Johnson And Johnson Quick Ratio (JNJ) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Johnson and Johnson  (NYSE: JNJ)

Johnson And Johnson's Quick Ratio

JNJ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 0.31 below Johnson And Johnson average.

Within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Johnson And Johnson in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2568, from total ranking in the second quarter 2026 at 3125.

Explain Quick Ratio?
How much Cash & cash equivalents JNJ´s has?
What are JNJ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/JNJ/financial-strength
https://api.csimarket.com/api/v1/companies/JNJ/fundamentals
https://api.csimarket.com/api/v1/companies/JNJ/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
JNJ Quick Ratio (Sep 27 2026)
Q3		 (Jun 28 2026)
Q2 		(Mar 29 2026)
Q1 		(Dec 28 2025)
Q4 		(Sep 28 2025)
Q3
Y / Y Current Liabilities Change 87.91 %
Y / Y Cash & cash equivalent Change -7.19 %
Quick Ratio MRQ 0.31
JNJ's Total Ranking # 2568
Seq. Current Liabilities Change 1.02 %
Seq. Cash & cash equivalent Change -18.33 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 407
Healthcare Sector # 783
Overall Market # 3039


Quick Ratio Statistics
High Average Low
2.62 0.98 0.21
(Jul 03 2016)   (Dec. 30. 2006)




Financial Statements
Johnson And Johnson's Current Liabilities $ 55,457 Millions Visit JNJ's Balance sheet
Johnson And Johnson's Cash & cash equivalent $ 17,228 Millions Visit JNJ's Balance sheet
Source of JNJ's Sales Visit JNJ's Sales by Geography


Cumulative Johnson And Johnson's Quick Ratio

JNJ's Quick Ratio for the trailling 12 Months

JNJ Quick Ratio

 (Sep 27 2026)
12 Months		 (Jun 28 2026)
12 Months 		(Mar 29 2026)
12 Months 		(Dec 28 2025)
12 Months 		(Sep 28 2025)
12 Months
Y / Y Current Liabilities TTM Growth 38.09 %
Y / Y Cash & cash equivalent TTM Growth -20.12 %
Quick Ratio TTM 0.44
Total Ranking TTM # 2331
Seq. Current Liabilities TTM Growth 16.35 %
Seq. Cash & cash equivalent TTM Growth -1.63 %

Quick ratio ranking by company, industry and sector >> Back to JNJ Financial Strength Comparisons >> Go to Compare JNJ Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $55,457.00 millions, cumulative Quick Ratio decreased to 0.44 below the Johnson And Johnson average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Johnson And Johnson. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4072.

Explain Quick Ratio?
How much Cash & cash equivalents JNJ´s has?
What are JNJ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 443
Healthcare Sector # 908
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.25 0.57 0.25
(June 30. 2006)   (Jan 01 2023)




Companies with similar Quick Ratio in the quarter ending Sep 27 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 27 2026 MRQ Cash & cash equivalentSep 27 2026 MRQ Current Liabilities
Aclaris Therapeutics Inc   0.84 $ 20.394  Millions$ 24.222  Millions
Seres Therapeutics Inc   0.84 $ 17.528  Millions$ 20.893  Millions
Jazz Pharmaceuticals Plc  0.80 $ 2,036.400  Millions$ 2,540.300  Millions
Zomedica Corp   0.80 $ 7.281  Millions$ 9.096  Millions
Pfizer Inc  0.79 $ 25,140.000  Millions$ 31,726.000  Millions
Xencor Inc  0.78 $ 59.622  Millions$ 76.266  Millions
Janux Therapeutics Inc   0.77 $ 41.818  Millions$ 54.247  Millions
Arcus Biosciences Inc   0.76 $ 151.000  Millions$ 199.000  Millions
Ligand Pharmaceuticals Incorporated  0.75 $ 374.303  Millions$ 500.569  Millions
Ionis Pharmaceuticals Inc   0.68 $ 296.303  Millions$ 435.292  Millions
Liquidia Corporation  0.68 $ 396.091  Millions$ 585.397  Millions
Bristol myers Squibb Company  0.67 $ 12,581.000  Millions$ 18,753.000  Millions
Harrow Inc   0.66 $ 75.336  Millions$ 114.224  Millions
Supernus Pharmaceuticals inc   0.62 $ 176.171  Millions$ 285.397  Millions
Axsome Therapeutics Inc   0.62 $ 313.859  Millions$ 509.719  Millions
Travere Therapeutics Inc   0.59 $ 123.542  Millions$ 210.912  Millions
Clene Inc   0.58 $ 9.887  Millions$ 17.114  Millions
Zoetis Inc   0.57 $ 1,533.000  Millions$ 2,682.000  Millions
Organon and Co   0.55 $ 1,455.000  Millions$ 2,652.000  Millions
Medicus Pharma Ltd   0.52 $ 5.020  Millions$ 9.743  Millions
Gossamer Bio Inc   0.51 $ 51.189  Millions$ 99.945  Millions
Bausch Health Companies Inc   0.51 $ 2,485.000  Millions$ 4,895.000  Millions
Neonc Technologies Holdings Inc   0.49 $ 10.966  Millions$ 22.241  Millions
Inovio Pharmaceuticals Inc   0.48 $ 49.786  Millions$ 102.842  Millions
Avenue Therapeutics Inc   0.47 $ 1.520  Millions$ 3.210  Millions
Royalty Pharma Plc  0.46 $ 544.857  Millions$ 1,179.003  Millions
Zymeworks Inc   0.45 $ 100.464  Millions$ 223.931  Millions
Organogenesis Holdings Inc   0.45 $ 21.326  Millions$ 47.649  Millions
Inmed Pharmaceuticals Inc  0.43 $ 1.140  Millions$ 2.673  Millions
Kiniksa Pharmaceuticals International Plc  0.43 $ 81.660  Millions$ 191.855  Millions

Date modified: 2026-10-22T05:13:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.